Skip to main content
Journal cover image

Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study.

Publication ,  Journal Article
Bluemke, DA; Sahani, D; Amendola, M; Balzer, T; Breuer, J; Brown, JJ; Casalino, DD; Davis, PL; Francis, IR; Krinsky, G; Lee, FT; Lu, D ...
Published in: Radiology
October 2005

PURPOSE: To assess prospectively the efficacy and safety of postcontrast magnetic resonance (MR) imaging with gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) compared with that of precontrast MR imaging in patients who are known to have or are suspected of having liver lesions and who are scheduled for hepatic surgery. MATERIALS AND METHODS: Investigational review board approval and written informed consent were obtained. HIPAA went into effect after data collection. A total of 172 patients were enrolled. After precontrast MR imaging, 169 patients (94 men, 75 women; mean age, 61 years; age range, 19-84 years) received an intravenous bolus of 25 micromol/kg Gd-EOB-DTPA and underwent dynamic gradient-recalled-echo and delayed MR imaging 20 minutes after injection. Arterial and portal phase computed tomography (CT) were performed within 6 weeks of MR imaging. The standard of reference was surgery with intraoperative ultrasonography (US) and biopsy and/or pathologic evaluation of resected liver segments and/or 3-month follow-up of nonresected segments if intraoperative US was not available. Three blinded reviewers and unblinded site investigators identified liver lesions on segment maps. The Wilcoxon signed rank test was used to compare differences in per-patient sensitivity of precontrast and postcontrast MR images. Adverse events were recorded, and patient monitoring and laboratory assay were performed at time of injection and up to 24 hours after contrast material administration. RESULTS: At MR imaging, 316 lesions were identified in 131 patients. In 77% (P = .012), 72% (P = .15), and 71% (P = .027) of patients for readers 1, 2, and 3, respectively, more lesions were seen at precontrast and postcontrast MR imaging combined than at precontrast MR imaging alone. Sensitivity values for blinded readings were significantly greater at postcontrast MR imaging than at precontrast MR imaging for two of three blinded readers. For all blinded readers, combined precontrast and postcontrast MR images showed no difference in sensitivity compared with helical CT scans. The use of MR imaging, however, yielded fewer patients with at least one false-positive lesion (37%, 31%, and 34% of patients for readers 1, 2, and 3, respectively) than did helical CT (45%, 36%, and 43% of patients for readers 1, 2, and 3, respectively). CONCLUSION: Compared with precontrast MR imaging, postcontrast MR imaging with Gd-EOB-DTPA demonstrated improved sensitivity for lesion detection in the majority of blinded readers, with no substantial adverse events.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Radiology

DOI

ISSN

0033-8419

Publication Date

October 2005

Volume

237

Issue

1

Start / End Page

89 / 98

Location

United States

Related Subject Headings

  • Tomography, X-Ray Computed
  • Sensitivity and Specificity
  • Safety
  • Nuclear Medicine & Medical Imaging
  • Multicenter Studies as Topic
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging
  • Liver Neoplasms
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bluemke, D. A., Sahani, D., Amendola, M., Balzer, T., Breuer, J., Brown, J. J., … Shamsi, K. (2005). Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology, 237(1), 89–98. https://doi.org/10.1148/radiol.2371031842
Bluemke, David A., Dushyant Sahani, Marco Amendola, Thomas Balzer, Josy Breuer, Jeffrey J. Brown, David D. Casalino, et al. “Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study.Radiology 237, no. 1 (October 2005): 89–98. https://doi.org/10.1148/radiol.2371031842.
Bluemke DA, Sahani D, Amendola M, Balzer T, Breuer J, Brown JJ, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology. 2005 Oct;237(1):89–98.
Bluemke, David A., et al. “Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study.Radiology, vol. 237, no. 1, Oct. 2005, pp. 89–98. Pubmed, doi:10.1148/radiol.2371031842.
Bluemke DA, Sahani D, Amendola M, Balzer T, Breuer J, Brown JJ, Casalino DD, Davis PL, Francis IR, Krinsky G, Lee FT, Lu D, Paulson EK, Schwartz LH, Siegelman ES, Small WC, Weber TM, Welber A, Shamsi K. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology. 2005 Oct;237(1):89–98.
Journal cover image

Published In

Radiology

DOI

ISSN

0033-8419

Publication Date

October 2005

Volume

237

Issue

1

Start / End Page

89 / 98

Location

United States

Related Subject Headings

  • Tomography, X-Ray Computed
  • Sensitivity and Specificity
  • Safety
  • Nuclear Medicine & Medical Imaging
  • Multicenter Studies as Topic
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging
  • Liver Neoplasms
  • Humans